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THE ROLE OF MICROGLIA AND TOLL-LIKE RECEPTOR-4 IN NEURONAL  
 
APOPTOSIS IN A SUBARACHNOID HEMORRHAGE MODEL 
 
ROBERT H. LEBLANC III 
 
ABSTRACT 
 
Background   
A subarachnoid hemorrhage (SAH) is a bleed into the subarachnoid space 
surrounding the brain.  This disease affects roughly 30,000 Americans each year and 
approximately one in six affected individuals die at the time of the ictal event.  
Individuals that do survive suffer from many complications including delayed cerebral 
vasospasm (DCV), cerebral edema, fever, and increased intracranial pressure (ICP) 
amongst others.  These patients often suffer from brain damage due to neuronal apoptosis 
as a consequence of excess neuroinflammation.  Microglia, the resident macrophage of 
the central nervous system, and Toll-like Receptor-4 (TLR4), a pro-inflammatory 
transmembrane receptor, have both been shown to play a role in the neuroinflammation 
seen in SAH.  RBC components have been shown to activate microglial TLR4, and this 
event is suggested to trigger downstream mechanisms leading to neuronal apoptosis.  The 
presented research takes a closer look at the role of microglial TLR4 in early neuronal 
apoptosis seen in an SAH model. 
 
Methods 
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 All mice used were 10- to 12-week-old males on a C57BL/6 background: 
TLR4−/−, MyD88−/−, TRIF−/− and wild type (WT). To induce an SAH, a total of 60 ul 
of arterial blood from a donor WT mouse was injected for over 30 seconds into another 
mouse.  For in vitro experiments, either primary microglia (PMG) or murine microglial 
BV2 cells were used.  Microglia were separated from murine neuronal HT22 cells by 
3um cell culture inserts or transwells, before being stimulated with lipopolysaccharide 
(LPS), red blood cells (RBCs), or RBC components including hemin (structurally similar 
to heme) and hemoglobin.  In vivo samples were studied using either 
immunohistochemistry (IHC) or Fluorescence Activated Cell Sorting (FACS), and in 
vitro cells were studied using IHC and Light Microscopy.  Neuronal cell death was 
measured using TUNEL and/or FloroJade C (FJC) assays.  Cognitive function after SAH 
was measured using the Barnes Maze protocol.  
 
Results 
In a 24-hour time course, more death occurred in the HT22 cells associated with 
BV2s treated with RBCs for 12-hour and 24-hour incubation time points as compared to 
1-hour and 3-hour time points. Similar results were seen in the WT PMGs, as HT22 
apoptosis increased in the RBC treated WT groups as the incubation time points 
increased.  The WT PMG and MyD88-/- RBC treated PMGs showed significant death as 
compared to a WT untreated control (p<0.05) using a FJC assay, and both showed more 
death in a TUNEL assay as compared to an untreated control. WT mice treated with 
whole blood and hemoglobin had significantly more apoptosis as compared with a 
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normal saline (NS)-treated control mouse (p<0.05). WT PMGs treated with whole blood 
and hemoglobin had more apoptosis as compared with an untreated control. MyD88-/- 
treated with RBC, hemoglobin, and hemin had more HT22 cell death compared with 
other genotypes treated with the same component. For the Barnes Maze, TLR4-/- mice 
performed significantly less total errors than WT mice on POD5 and 6 (p<0.01), and took 
significantly less time to reach the goal chamber on POD4, POD5 (p<0.05), and POD6 
(p<0.01). 
 
Conclusion 
 Our experimental results suggest that a microglial TLR4-dependent, MyD88-
independent pathway is involved in neuronal apoptosis very early in an SAH model via 
RBC and hemoglobin activation, and that neuronal cell apoptosis due to TLR4 expression 
may be related to SAH-related cognitive and behavioral deficits.  Our results suggest that 
TRIF may be the intracellular adaptor that is involved in this mechanism, but further 
experiments are needed to confirm this. 
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INTRODUCTION 
Central Nervous System Anatomy and Physiology Review 
Underneath the periosteum and bone of the skull, there is a layer surrounding the 
brain called the meninges.  The meninges are a set of three membranes; their primary role 
is to protect the brain and spinal cord.  The three layers from most superficial to deepest 
are the dura mater, arachnoid, and pia mater.  A cavity called the subarachnoid space lies 
below the arachnoid layer and above the pia mater.  The subarachnoid space is filled with 
cerebrospinal fluid (CSF), which serves many important functions.  CSF maintains the 
chemical homeostasis of the brain and spinal cord, protects the cerebrum from impact, 
and reduces the net weight of the brain inside the skull (Saladin, 2007).  Key to brain 
stability is the fact that the volume of subarachnoid CSF is limited, so that intracranial 
pressure (ICP) does not increase beyond a hazardous level.  This prevents cerebral 
ischemia or lack of blood flow to the brain. 
The Circle of Willis (CoW) is a group of major arteries that supplies many 
cerebral regions.  The CoW is made up of the anterior cerebral arteries (ACA), anterior 
communicating artery, internal carotid arteries (ICA), posterior cerebral arteries (PCA), 
and posterior communicating arteries (Purves et al., 2008). CoW arterial supply for some 
cerebral areas is redundant, so that if one artery is blocked, blood can re-distribute to 
dilated vessels supplying that same cerebral location.  This helps to prevent excess brain 
damage due to cerebral ischemia (Boorder et al., 2006).  This mechanism however is 
limited, and excess vessel blockage will causes cerebral ischemia. The CoW arteries pass 
through the subarachnoid space, which allows for exchange of materials between the 
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blood vessels and the CSF, without having blood directly enter the subarachnoid space.  
Another important set of vessels that is not considered part of the CoW, but that runs 
through the subarachnoid space to supply the cerebrum, are the left and right middle 
cerebral arteries (MCA).  If blood enters the subarachnoid space due to a vessel wall 
disruption either caused by trauma (Parrillo, 2013) or aneurysm rupture (van Gijn et al., 
2007), a subarachnoid hemorrhage (SAH) will occur.  Often the vessels involved are the 
major arteries of the CoW, left or right MCA, or branches of CoW and MCA vessels (van 
Gikn et al., 2007).  SAH leads to many pathological consequences, which will be 
discussed in future sections. 
 
Aneurysmal Subarachnoid Hemorrhage Definition, Statistics, and Risk Factors 
There are approximately 800,000 strokes per year in the United States, with a 
total mortality of about 42 deaths per a 100,000 population.  Americans die from a stroke 
about every 4 minutes, and stroke ranks fourth as a leading cause of death.  In the United 
States, about 640,000 (80%) of total ictal events are ischemic strokes (IS) and about 
160,000 (20%) are hemorrhagic strokes (American Heart and Stroke Associations, 2014), 
(Center for Disease Control and Prevention, 2014).  Of these 160,000 hemorrhagic 
strokes, about 30,000 are defined as an aneurysmal SAH (aSAH) (Brain Aneurysm 
Foundation, 2014).  An aSAH occurs when an arterial wall of the brain weakens and then 
ruptures, which coats the cerebrum in blood and has many dangerous sequalae.  aSAH is a 
devastating disease that has morbidity and mortality rates higher than 50% (Fujii et al., 
2013), and approximately 1 in 6 patients die at the time of bleeding with the surviving 
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patients typically experiencing major complications such as re-bleeds (Rabinstein, 2013).  
The lifetime cost per person of first SAH occurrence in 1990 was estimated to be over 
$220,000, which was higher than both intracerebral hemorrhage (ICH) and IS (Taylor et 
al., 1996). 
An aSAH is caused by the rupture of an aneurysm, which is a weakened, enlarged 
area in the artery (van Gijn et al., 2007), while a non-aneurysmal subarachnoid 
hemorrhage (naSAH) is caused by other reasons such as trauma (Parrillo, 2013).  Up to 
5% of adults in the general population have or will develop a cerebral aneurysm with 
potential to burst and cause an aSAH (King, 1997).  There are certain genetic and 
behavioral risk factors that make individuals more likely to have an ictal event, although 
unexpected attacks can occur.  In particular, hypertension and regular cigarette smoking 
are well-accepted aSAH risk factors (National Institute of Health, 2013).  Other risk 
factors suggested for aSAH include female gender, increasing age, increased alcohol 
consumption, and additional genetic factors (King, 1997). 
 
Aneurysm and Aneurysmal Subarachnoid Hemorrhage Review 
Aneurysms are classified by size and shape.  Small aneurysms are less than 11 
millimeters in diameter; large aneurysms are up to 25 millimeters in diameter; and giant 
aneurysms are greater than 25 millimeters in diameter.  There are three types of cerebral 
aneurysms based on shape: saccular aneurysms are rounded and are the most common 
type; lateral aneurysms project out of an artery’s side; and fusiform aneurysms are a 
widening along the walls of a vessel (National Institute of Health, 2014).  Large 
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aneurysms may begin to produce headaches and giant aneurysms may put pressure on the 
brain and nerves causing various symptoms.  If the aneurysm is discovered before it 
ruptures via computed topographic angiography (CTA), magnetic resonance angiography 
(MRA), or a diagnostic cerebral angiogram, the patient may have the opportunity to 
undergo medical therapy or neurosurgery in order to treat the aneurysm and keep it from 
bursting (American Heart and Stroke Associations, 2012).  If an ictal event occurs before 
detection, these diagnostic techniques are also used to help guide doctors in treatment of 
aSAH. 
Often patients do not find out about their aneurysm until it bursts or when an 
aSAH event has occurred (National Institute of Health, 2014).  When an aneurysm bursts 
the high amounts of pressure from the larger arteries pushes blood out of the tear in the 
vessel wall, and into the subarachnoid space.  When blood surrounds the arteries in the 
subarachnoid space, the brain is in a pathological state and consequences typically follow 
(Brain Aneurysm Foundation, 2014). It is not exactly known how much blood in the 
subarachnoid space is needed to cause an ictal event or how much is needed to cause each 
symptom and/or pathological consequence; but typically if an aneurysm bursts, an aSAH 
follows. 
 
Subarachnoid Hemorrhage Clinical Symptoms and Diagnosis 
SAH is often followed by many clinical manifestations.  The first event of an 
SAH is a bleed into the subarachnoid space where the CSF is located, which causes 
breakdown of the normal physiological mechanism to keep pressure low around the 
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cerebrum.  This causes a sudden increase in ICP, which is often felt by patients as a 
severe headache described as a “thunderclap headache” because of the severity and quick 
onset (Rabinstein, 2013).  As the blood continues to enter the subarachnoid space, the 
patient may feel confused, may vomit, and may experience seizures (van Gijn et al., 
2007). Other signs and symptoms of SAH include sudden numbness or weakness, blurry 
vision, and dizziness (National Institute of Health, 2014).   
Patients often continue to have cerebral edema or hydrocephalus in the days 
following the ictal event due to blood and excess fluid in the subarachnoid space.  This 
can continue to cause increased ICP and brain damage (National Health Services, 2014).  
About 4 to 12 days after the ictal event, a majority of SAH patients undergo a 
phenomenon known as a delayed cerebral vasospasm (DCV), which causes 
complications when treating SAH patients (Heros et al., 1983).  DCV in SAH causes the 
radius of the affected cerebral artery to decrease.  The affected artery constricts, which 
causes cerebral ischemia and hypoxia (Ciurea et al., 2013).  DCV is often the origin of 
many adverse events related to SAH including brain damage and death. 
 Another anomaly that SAH patients often face is fever (Naidech et al., 2008), 
which is known to have a negative impact on patient outcome (Badjatia, 2009). 
Intraventricular blood as a consequence of aSAH has been shown to be a risk factor for 
developing fever (Dorhout et al., 2008).  Fever after SAH is associated with functional 
disability, cognitive impairment, and increased mortality (Fernandez et al., 2007).  Fever 
has also been suggested to have an association with DCV in SAH patients (Oliveira-
Filho, 2001).  Currently, SAH-related fever is treated with body cooling techniques and 
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antipyretic medication (Scaravilli et al., 2011), although these treatment methods are 
often unsuccessful.  SAH-related fever is not well understood and future research is still 
needed to elucidate fever treatment. 
SAH symptoms can overlap with those associated with the other type of cerebral 
hemorrhage, ICH as well as IS (Cedars-Sinai, 2014).  Since SAH has different 
treatments, it is important to determine which type of stroke the patient is having.  SAH is 
clinically confirmed using Computed Tomography (CT) or Magnetic Resonance Imaging 
(MRI) scanning techniques.  Lumbar punctures can also be used to rule out other 
potential diagnoses (Cedars-Sinai, 2014).  It is important to rapidly determine the severity 
of the initial bleed, as this is the best-known indicator of SAH outcome as well as to 
establish the degree of neurological impairment using an SAH grading system.  This is 
useful for prognosis and treatment procedure purposes (Bederson et al., 2009).   
 
Subarachnoid Hemorrhage Treatment and Outcome 
The treatment for SAH varies between patients, and depends on the cause of the 
bleed and extent of brain damage.  Patients often spend up to 10 to 15 days in the 
Neurointesive Care Unit (N-ICU), where specialists monitor for complications such as re-
bleeds, vasospasm, and hydrocephalus.  The initial protocol for SAH treatment is to 
maintain adequate breathing and circulation.  Next, the neurosurgeons may look to stop 
the bleed or prevent re-bleeding via surgical clipping or endovascular coiling surgery.  
Surgical clipping is when a titanium clip is placed at the base of the aneurysm, and 
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endovascular coiling is when a platinum coil is put into the aneurysm (Bederson et al., 
2009).  
The remainder of immediate SAH treatment at the N-ICU focuses on controlling 
hydrocephalus and vasospasm.  To reduce the hydrocephalus, excess CSF and blood are 
drained via a lumbar drain inserted into the subarachnoid space of the spinal canal or a 
ventricular drain inserted into the brain ventricles (Bederson et al., 2009).  Treatment and 
prevention of SAH vasospasm is limited.  Physicians typically monitor for signs of 
vasospasm using a Transcranial Doppler (TCD).   A TCD is an ultrasound technique that 
uses a pulsed Doppler transducer for the assessment of intracerebral blood flow (Sarkar et 
al., 2007).  Patients are often administered a calcium channel antagonist such as nimodipine 
to treat vasospasm (Chowdhury et al., 2013).  If the vasospasm persists, neurosurgeons may 
choose to perform balloon angioplasty in order to open the affected artery (Andaluz et al., 
2002). 
SAH patients often have post-event complications, which depend on the cerebral 
area supplied by the affected artery.  These issues can include memory disturbances, 
executive deficits, delirium, and post-stroke mania and depression (Brainin & Heiss, 
2010).  Treatment for these post-event symptoms includes physical therapy, occupational 
therapy, and psychological evaluation and clinical counseling (Brainin & Heiss, 2010).  
Even though SAH follow-up events are attended to with current SAH treatment, overall 
neurological outcome in most SAH patients remains poor (Ingelmo et al., 2010).   
Additional research is needed to study SAH pathology, in order to improve treatment 
methods. 
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Subarachnoid Hemorrhage Clinical Characteristics 
After an SAH, many complex pathways are stimulated to produce a process called 
Early Brain Injury (EBI), which leads to neuronal apoptosis.  EBI entails many clinical 
consequences including increased ICP, decreased cerebral blood flow, and global cerebral 
ischemia.  These physiological issues lead to cell death by disrupting the blood-brain barrier 
(BBB), causing neuroinflammation or inflammation of nervous system, and initiating 
oxidative cascades (Fujii et al., 2013). In a 24-hour rat SAH model, there was significant 
EBI as shown by increased ICP, BBB permeability, and brain edema, which produced 
high mortality (Kusaka et al., 2004).  A blood shunt rabbit SAH model revealed a 
significant decrease in cerebral perfusion pressure (CPP) and bilateral regional blood flow 
caused by ICP during EBI as well as increased basilar endothelial cell apoptosis, and cell 
death in the basal cortex and hippocampus (Marbacher et al., 2012).  EBI has also been 
suggested to play a role in SAH-related DCV (Cahill et al., 2006; Nishizawa, 2013), 
Although much of the available literature considers cell death, including neuronal 
apoptosis through both intrinsic and extrinsic pathways, to be a crucial factor in the clinical 
consequences of EBI in SAH, little detailed investigation into the subject has been 
conducted (Hasegawa et al., 2011). Chowdhury reports that some of the currently proposed 
mechanisms that lead to EBI include oxidative injury, nitric oxide dysregulation, activation 
of pro-inflammatory markers such as interleukin-1beta (IL-1B) and vascular endothelial 
growth factor (VEGF), and iron overload after hemoglobin degradation (Chowdhury et al., 
2013).  One proposed protective mechanism against SAH EBI and neuroinflammation is 
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that of autophagy activation that likely works through an anti-apoptotic system (Jing et al., 
2012). 
An important pathophysiological EBI outcome is neuroinflammation.  
Neuroinflammation after SAH is first triggered by the innate immune system (Emsley & 
Tyrrell, 2002), and often leads to adverse consequences such as neuronal apoptosis, brain 
edema, and swelling.  Neuroinflammation not only appears to play a role in SAH 
pathology after an ictal event, but may also increase the risk of having an episode 
(Emsley & Tyrrell, 2002).  SAH is known to not only cause inflammation in the nervous 
tissue, but also in the lungs of both human and animal models (Cobelens et al., 2010), and 
the intestinal tract of some animal models (Zhou et al., 2007). 
Neuroinflammation due to SAH is thought to play a role in many of the adverse 
issues including increased ICP, DCV, and neuronal cell death.  For example, 
neuroinflammation is thought to initiate cell death of hippocampus neurons, which leads 
to the memory loss seen in many SAH patients (Brainin & Heiss, 2010).  One study of 
experimental SAH in a mouse model reports inflammation in post-operative surviving 
mice indicated by increased pro-inflammatory cytokines such as Tumor Necrosis Factor- 
alpha (TNF-a) and inflammatory mediators such as intercellular adhesion molecule-1 
(ICAM-1), which is an adhesion molecule that aids immune cells in exiting the 
bloodstream and accessing inflammatory sites in tissue.  The same study showed a 
correlation between duration of cerebral ischemia and degree of inflammation, and areas 
of neuroinflammation showed deoxyribonucleic acid (DNA) fragmentation or cell 
apoptosis (Prunell et al., 2005). Neuroinflammation induced by SAH is long lasting; one 
	  	   10	  
study showed SAH neuroinflammation to be present 21 days after the ictal event 
(Kooijman et al., 2014). 
 
Cells and Biomarkers Involved in Neuroinflammation 
Now that the basics of SAH have been established, a review of both the cells and 
biomarkers involved in this disease must be done in order to fully understand its 
pathology.  The innate immune system responds similarly to a vast array of CNS 
pathologies including infection, trauma, IS, ICH, and SAH (Buchanan et al., 2010).  A 
key event in these CNS conditions is the activation of cells, which produce pro-
inflammatory soluble mediators.  Microglia and astrocytes are both glial cells that are 
involved in neuroinflammation. 
Microglia are the resident macrophages of the CNS.  These cells are key in 
ingesting and eliminating microbes and dead cells, displaying antigens to adaptive 
immune cells such as T-lymphocytes or T cells, responding to T cell signaling, secreting 
inflammatory mediators such as TNF-a and Interleukin-1 (IL-1), and initiating tissue 
repair (Kumar et al., 2013). Microglia are known to mediate many events in 
neuroinflammation including cytotoxicity, repair, regeneration, and immunosupression 
(Chhor et al., 2013).   Astrocytes are the most abundant cell in the cerebrum, and make 
up a significant portion of the BBB.  They help regulate the CNS extracellular 
environment and act as neuronal support cells.  During neuroinflammation, astrocytes are 
activated by signals released from microglia (Mayer, 2013).  In a spinal cord injury 
model, astrocytes were shown to promote entry of neutrophils and monocytes in the 
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peripheral blood (Pineau et al., 2010; Kumar et al., 2013).  Recent research suggests that 
there is a key interaction between astrocytes and microglia in initiating and maintaining 
neuroinflammation in CNS pathologies (Barbierato et al., 2013).  For example, the 
astrocyte response to a pro-inflammatory receptor called Toll-like Receptor-4 (TLR4) 
was found to be completely dependent on functional microglia (Holm et al., 2012).  More 
on the TLR4 pathway will be discussed in a later section. 
Neutrophils, another innate immune cell which are also capable of engulfing and 
neutralizing pathogens as well as secreting pro-inflammatory mediators (Kumar et al., 
2013), have been shown to play a role in experimental SAH-induced acute lung 
inflammation (Cobelens et al., 2010).  However, their role in SAH neuroinflammation is 
most likely minor.  Until recently, neurons were thought to play a passive role in 
neuroinflammation.   Recent research shows that neurons become activated via pro-
inflammatory pathways and secrete cytokines such as TNF-a and interleukin-6 (IL-6).  
Activated neurons also increased neutrophil migration across the vessel endothelial 
monolayer via increased expression of adhesion molecules such as ICAM-1 on endothelial 
cells (Leow-Dyke et al., 2012).  Other research has shown that the neurons possess 
protective mechanisms, which promote self-survival during the early phase of SAH 
neuroinflammation (Endo et al., 2006).  
 
Toll-like Receptor-4 and Related Biomarkers - Classic Pathway 
The Toll-like receptor (TLR) mediated intracellular signaling pathways have been 
identified to play a critical role in the inflammatory processes of the central nervous system 
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(Lee et al., 2002).  One particular TLR that is important in many CNS pathologies is TLR4.  
Microglia cells contain TLR4 receptors, and the microglia activation via TLR4 is a key 
event in many CNS pathologies (Buchanan et al., 2010).  Although TLR4 expression has 
been shown in astrocytes (Gorina et al., 2011), and even neurons (Leow-Dyke et al., 
2012) and endothelial cells (Zhou et al., 2009; Jayakumar et al., 2014), microglial TLR4 
seems to be most important in mediating neuroinflammation (Lehnardt, 2010). 
  Toll-like receptor-4 is a transmembrane receptor that plays a crucial role in 
pathogen recognition and activation of innate immune system.  TLR4 is highly conserved 
across species from Drosophila fly to mus muscularis or house mouse to homo sapiens or 
humans (HUGO Gene Nomenclature Committee, 2014).  TLR4 is activated by pathogen-
associated molecular patterns (PAMPs) expressed on infectious agents such bacteria and 
viruses. TLR4 has been proven to be a key innate immune system activator in both 
humans and mice, but vast research suggests TLR4 as also being key in IS 
neuroinflammation and SAH DCV.  One such example is a mouse model of subacute 
stress and experimental stroke via MCA occlusion, where TLR4 was found to play a key 
role in initiating neuroinflammation and worsening behavioral outcome (Caso et al., 
2008).  TLR4 pro-inflammatory intracellular signaling molecules such as nuclear factor-
kappa B (NF-kB), and cytokines such as TNF-a and IL-1B have been shown to be critical 
in mediating neuroinflammation, and have been recently considered for therapeutic target 
for CNS pathology (Falip et al., 2013). 
Lipopolysaccharide (LPS) is found on the external membrane of gram-negative 
bacteria (Poltorak et al., 1998). LPS is a well-accepted TLR4 activator, and is known as 
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the classical TLR4 agonist (Sasai et al., 2013).   Ligand activation has been shown to 
induce a TLR4 conformational change, which leads to the cytoplasmic Toll/Interleukin 1 
receptor (TIR) signaling domain to be expressed on TLR4 (Nunez Miguel et al., 2007).  
TLR4 and its adaptor proteins each contain a TIR domain, which allows for different 
interactions between them (Bovijn et al., 2013).  Like other transmembrane type I 
receptors, TLR4 has the potential to form homo-or heterodimers.  A CD36-TLR4-TLR6 
heterodimer was recognized as a mechanism by which oxidized low-density lipoprotein 
(LDL) and amyloid-beta stimulate inflammation (Stewart et al., 2010). 
TLR4 forms a heterodimer with a co-receptor called lymphocyte antigen 96 or 
more commonly known as MD-2, to form a TLR4-MD-2 complex (Kim et al., 2007) in 
both humans and mice, and allows for responsiveness to the LPS molecule (HUGO Gene 
Nomenclature Committee, 2014).  Although MD-2 can multimerize, it has been shown 
that monomeric MD-2 preferentially binds TLR4 and confers more efficient LPS 
responsiveness (Re et al., 2002).  TLR4-MD-2 complex recognizes a common pattern 
between different LPS molecules (Park et al., 2009), and MD-2 has been suggested to 
play a crucial role in neutralization of these endotoxins (HUGO Gene Nomenclature 
Committee, 2014). The TLR4-MD-2 complex recognizes LPS via structural information, 
and determines the endotoxicity through acylation and phosphorylation patterns of the 
LPS molecule that it binds (Gangloff & Gay, 2004).   
CD14 is a surface receptor expressed mainly on monocytes, macrophages, and 
microglia in both humans and mice, that interacts with other proteins and surface 
receptors to mediate innate immune responses (HUGO Gene Nomenclature Committee, 
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2014).  It was suggested to present concentrated endotoxin molecules such as LPS, to a 
TLR4-MD-2 complex, in order to activate it (Miyake, 2003).  CD14 was later confirmed 
to play a crucial role in concentrating LPS signaling, and was shown to be required for 
the LPS-induced activation of the Myeloid differentiation protein 88  (MyD88) 
independent pathway called the Toll-like Receptor associated activator of interferon 
(TRIF) pathway (Jiang et al., 2005).  
Another important protein in human and mouse TLR4 signaling is 
lipopolysaccharide-binding protein (LBP).  This protein binds LPS and interacts with 
CD14, and is suggested to regulate LPS-dependent monocyte response.  It has been 
shown in a mouse model to be necessary for the rapid acute-phase response to LPS 
(HUGO Gene Nomenclature Committee, 2014). 
 
Toll-like Receptor-4 Intracellular Signaling – Classic Pathway 
MyD88 and TIR domain-containing adaptor molecule 1 (TICAM-1) also known 
as TRIF are cytosolic adaptor proteins that play a crucial role in intracellular signaling in 
immune cells of both humans and mice.  MyD88 has been shown to carry an N-terminal 
death domain and a C-terminal TIR domain, which allows it to transduce signals from the 
Interleukin-1 Receptor and a majority of the Toll-like Receptor family including TLR4.  
TRIF also contains a TIR domain but has been shown to only interact with the 
intracellular portions of TLR3 and TLR4 (HUGO Gene Nomenclature Committee, 2014). 
MyD88 and TRIF have both been experimentally shown to be involved in TLR4/ 
NF-kB mediated inflammation.  Specifically, Myd88 and TRIF serve as intermediates in 
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the TLR4/NF-kB pathway to mediate cytokine production after cerebral ischemia  
(Famakin et al., 2012).  The MyD88-mediated pathway activates NF-kB signaling and in 
turn, cytokine secretion and inflammation.  The TRIF-mediated pathway activates 
delayed NF-kB inflammatory signaling, cytokine production, and cell apoptosis 
(Fitzgerald et al., 2003; Yamamoto et al., 2003; O’Neill et al., 2007; O’Neill et al., 2013).  
 NF-kB is a pro-inflammatory transcription factor involved in both the innate and 
adaptive divisions of the immune system, found in a majority of mammalian cells.  It is 
composed of two subunits, namely p50 and p65 (Scott et al., 1993).  One of the main 
functions of NF-kB is to control gene expression of pro-inflammatory factors including 
cytokines such as TNF-alpha, IL-1, and IL-6, which are produced by many nucleated 
cells, particularly endothelial cells, epithelial cells, and resident macrophages (Boyle, 
2005).  Microglia have been shown to mediate neuroinflammation via the NF-kB 
pathway (Yao et al., 2013), and TLR4-mediated NF-kB signaling has been shown to 
participate in hemorrhagic inflammation (Teng et al., 2009). Microglial NF-kB subunit 
p65 and TLR4 expression along with production of TNF-a, IL-1B, and IL-6 were shown 
to experience post-SAH biphasic changes in a rat model, with a 2-6 hour peak and a 12-
48 hour sustained elevation.  This shows that neuroinflammation has certain patterns and 
may be important in the treatment of SAH patients (Ma et al., 2009). 
 
Toll-like Receptor-4 Relevance in CNS Disease States 
As stated, TLR4 is essential in triggering post-ischemic inflammation and 
activating immune cells in the CNS (Trotta et al., 2014).  Microglial TLR4 activation is 
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thought to play some role in sickness behavior and excessive neuroinflammation in a 
majority of CNS pathologies by mediating cytokine production (Hines et al., 2013). 
TLR4 has been suggested as a therapeutic target for neuroinflammation in many CNS 
pathologies to alleviate infection (Zhou et al., 2012), ischemia-reperfusion injury (Bell et 
al., 2013), traumatic brain injury (Ahmad, 2013), epilepsy (Pernhorst et al., 2013), 
chronic pain conditions (Chopra et al., 2013), neuropathic pain (Jia et al., 2012; Kuang et 
al., 2012), and hemorrhagic stroke (Teng et al., 2009; Hanafy 2013).  TLR4 has also been 
shown to play a crucial role in the pathology of neurodegenerative disorders such as 
Parkinson’s Disease (Noelker et al., 2013) and Alzheimer’s Disease (Walter et al., 2007).   
Recent research suggests a role of TLR4 in epilepsy.  An abundance of TLR4 expression 
was related to seizure frequency per month in an experimental model (Pernhorst et al., 
2013).  TLR4 has even been implicated in neuroinflammation and other physiological 
complications due to chronic ethanol intake (Alfonso-Loeches et al., 2010; Alfonso-
Loeches et al., 2012).  In a majority of these pathological states, research shows TLR4 as 
a mediator of poor outcome in mice and humans.  
 
Toll-like Receptor-4 Relevance in Subarachnoid Hemorrhage 
 There is now evidence from animal models that the EBI, neuroinflammation, 
vasospasms, and neuronal apoptosis that come with SAH have TLR4 pathway involvement. 
It was shown that TLR signaling was significantly increased in a ruptured human saccular 
intracranial wall (Kurki et al., 2011).  TLR4 along with Myd88 and TRIF, were revealed to 
mediate pathway-specific cytokine production after cerebral ischemia (Famakin et al., 
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2012; Wang et al., 2013).  Experimental SAH produced in rat models showed a significant 
up-regulation of TLR4/NF-kappaB signaling pathway during the early injury phase of SAH 
(Ma et al., 2009).  Elevated expression of TLR4 in the basilar arteries of rabbits was 
detected after SAH and was most prominent at days 3 and 5 (Zhou et al., 2007).  LPS 
administration before aSAH worsened delayed deterioration associated with DCV and 
cognitive performance (Smithason et al., 2012), showing that TLR4 activation can 
worsen aSAH pathology.  
In the past decade, other molecules besides LPS, have been shown to be activators 
of TLR4 including beta-amyloid, oxidized LDL, Angiotensin II, and saturated fatty acid 
among others (Trotta et al., 2014). All aSAH patients will have a cerebral inflammatory 
response as a result of red blood cells’ (RBCs) break down products introduced into the 
subarachnoid space (Hanafy, 2010).  Recent research has shown RBC products such as 
heme and hemoglobin to be activators of TLR4 as well.  
 In 2007, Figueiredo et al. showed that heme-induced TNF-a secretion by 
macrophages depended on the TLR4/CD14 pathway via MyD88 signaling.  This research 
was further proven by Fortes et al. (2012) who showed that heme-induced programmed 
necrosis on macrophages through autocrine TNF-a activation was TLR4/Myd88 
dependent.  Heme was then shown to directly activate TLR4 neuroinflammation via 
MyD88 and TRIF pathways in an ICH model (Lin et al., 2012), and heme-induced cell 
death was revealed to be dependent on IL-1 in an SAH model (Greenhalgh et al., 2012). 
Most recently, heme was revealed to trigger TLR4 signaling leading to endothelial cell 
activation and vaso-occlusion in murine sickle cell disease (Belcher et al., 2014). 
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In 2010, Wu et al. showed that after vascular smooth muscle was incubated with 
oxyhemoglobin for 48 hours, TLR4 expression and TNF-a production both increased.  
Further studies revealed that hemoglobin induced neuroinflammation after 
methemoglobin formation in a preterm intraventricular hemorrhage model, and a TLR4 
role was suggested (Gram et al., 2013).  Most recently in 2014, Wang et al proved that 
hemoglobin initiated the formation of a Toll-like Receptor-2/TLR4 heterodimer in an 
ICH model, and suggested this to be key in hemorrhagic neuroinflammation. 
MyD88 has been shown to be up-regulated in the cerebral cortex on days 1 and 5 
post-SAH as well as a parallel up-regulation of IL-1B (Sun et al., 2013).  Most recently, 
the results from an aSAH mouse model showed that the neuronal cell apoptosis and DCV 
that accompany aSAH are microglial TLR4 dependent through MyD88 and TRIF mediated 
pathways (Hanafy, 2013).  The present thesis results are an extension of Hanafy (2013) and 
attempt to take a closer look at the blood-activated microglial TLR4 pathway and its 
involvement in SAH-induced neuronal apoptosis. 
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METHODS 
I have been given full permission by Dr. Khalid Hanafy to describe any protocols 
that his lab has either designed or edited for optimization.  Credit has been given when 
appropriate.  Methods described are based on Dr. Hanafy (2013) and unpublished 
protocols. 
 
Animals  
All animal experiments were approved for use by the Beth Israel Deaconess 
Medical Center Institutional Animal Care and Use Committee and performed in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. All mice were 10- to 12-week-old males on a C57BL/6 background: 
TLR4−/−, MyD88−/−, TRIF−/− and wild type (WT) (Jackson Laboratory, Bar Harbor, 
ME) (Hanafy, 2013). 
 
Primary Microglia Culture and BV2 Cell Line 
Primary microglia (PMG) were isolated using a modified version of previously 
described protocol (Moussaud & Draheim, 2010).  Microglia were harvested from 
neonatal mice (P0-P5) using the Papain Dissociation Kit (Worthington Biomedical 
Corporation, Lakewood Township, NJ).  After the cells were harvested, microglia were 
re-suspended in DMEM-10% FBS containing 1 ng/ml macrophage colony-stimulating 
factor (M-CSF).  The final cell culture is primarily microglia cells floating on top of an 
astrocyte bed.  Microglia were collected from these cell culture plates and placed on a 
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new plate.  In some in vitro experiments, a murine microglial BV2 cell line was used in 
place of PMGs (Hanafy, 2013). 
 
SAH 
The subarachnoid hemorrhage model completed is a modified version of a 
previously described protocol (Sabri et al., 2009).  Before SAH was induced on the mice, 
they were anesthetized with xylazine (10 mg/kg) and ketamine (12 mg/kg).  The mice 
were then placed in a stereotaxic instrument, where a midline scalp incision was 
executed. A burr hole was drilled 3.5 mm anterior to the bregma, which is a visible 
marker on the skull of the mouse.  Drilling was done until the dura was breached. A 27-
gauge spinal needle was advanced ventrally at a 45° angle to a depth of 5 mm 
dorsoventral. A total of 60 ul of arterial blood from a donor WT mouse was injected for 
over 30 seconds (Hanafy, 2013). 
 
Immunohistochemistry (in vivo and in vitro): TUNEL and FloroJade C staining 
Adult male C57BL/6 were sedated with an Avertin overdose (250 mg/kg), 
followed by perfusion with ice-cold PBS. The brains were fixed and then cut into 8 um 
coronal serial sections with a Leica CM3050 S cryostat.  TUNEL and FloroJade (FJC) 
staining were performed as per instructions.  DAPI was used to stain the nucleus for in 
vitro immunohistochemistry (IHC).  Fluorescent microscopy was done on a Zeiss Axio 
Scope (Carl Zeiss, Inc., Thornwood, NY). Brightness and contrast of images were 
adjusted in Image J software (Hanafy, 2013).   
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Transwell Experiment Set Up 
18mm sterilized cover slips were placed into 3um cell culture inserts or 
transwells.  These transwells were then placed into 6-well cell culture plates until the day 
of the experiment.  PMG cells were then harvested and placed in the transwells with a 
final media volume of 2mL.  24mm sterilized cover slips were placed into separate 6-well 
cell culture plates.  HT22 cells (murine neuronal cell line) were grown on these 24mm 
cover slips with a final media volume of 3mL. On the day of the experiment, the 
transwells with PMG cells were placed on top of the cell culture wells with HT22 cells.  
All pretreatments and treatments were done on the PMGs in the transwells.  See Figure 1 
for method demonstration (Hanafy, unpublished). 
	  
	  
Figure 1: Transwell Set-up.  PMGs or BV2s were placed into the transwell on top of a 18mm 
cover slip.  The transwell was filled with 2mL of complete media.  The transwell was placed into 
another well with HT22 cells plated at the bottom.  This well was filled with 3mL of complete 
media (Chan et al., 2009; Hanafy, unpublished). 
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Fluorescence Activated Cell Sorting (FACS) 
 
 Cells were harvested into translucent FACS tubes using 1X Trypsin and cell 
scrapers.  Cells were washed using FACS Buffer after this step as well as all incubation 
steps.  Cells were incubated on ice with CD16/32 antibody for 15 minutes to block all 
unspecific binding sites.  Cells were incubated on ice with primary antibodies for 30 
minutes.  This allows for detection of cell surface markers including CD11b, which is a 
biomarker specific for macrophages and microglia.  The final cell pellet was resuspended 
in 500ul of FACS Buffer for flow cytometry using a FACS machine (BD Biosciences, 
San Jose, CA).  FACS is a method of flow cytometry that sorts cells into different 
categories based on specific light scattering and fluorescent characteristics for each cell.  
Antibodies are detected in different channels, and these populations are sorted out. Based 
on this sorting, FACS is able to quantify the number of cells present in a sample as well 
as the percent of cells positive for a specific biomarker.  Analysis of FACS data was 
completed using FloJo software (Hanafy, unpublished).  
 
Barnes Maze Protocol 
 The Barnes Maze protocol is a test of in vivo cognitive function in a mouse 
model.  The presented Barnes Maze protocol is a modified version of a previously 
described method (Sunyer et al., 2007).  A circular platform with equally spaced holes is 
placed on a stand 105 cm above the floor.  The platform is surrounded by four black and 
white visual cues.  A goal chamber with pieces of mouse food is placed under one of the 
holes.  All other holes are left open with no chambers below them. The goal is for the 
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mice to find the correct hole with the chamber below, and for the mouse to get into the 
chamber.  The chamber is always placed into the same spot during this phase and during 
post-operative days 1-3.  A 7-day training or acquisition period is done to allow the 
mouse proper time to learn the technique of getting into the hole.  During this time, each 
mouse is given three trials.  The primary latency, total latency, primary errors, and total 
errors are measures of performance.  The primary latency is the time it takes for the 
mouse to first find the goal while the total latency is the total time it takes the mouse to 
get into the goal.  The primary errors are the number of times the mouse goes to an 
incorrect hole before first finding the goal while the total errors is the total times the 
mouse goes to an incorrect goal.  The mouse is allowed a maximum of 180 seconds to 
find the goal.  After the acquisition period, an SAH is given to the mice.  No trials are 
done on the day of surgery.  The day after surgery, a 7-day post-operative phase begins.  
During the post-operative phase, only one trial is allowed for each mouse.  On the fourth 
post-operative day, a technique called spatial reversal is applied.  The spatial reversal 
consists of a 180-degree turn in relation to the visual cues, which places the goal chamber 
at the opposite side from where it had been originally located in previous trials.  The goal 
chamber remains in this new position for post-operative days 4-7 (Hanafy, unpublished). 
 
Light Microscopy 
In vitro cell culture experiments were viewed using a Zeiss Light Microscope, and 
images were taken using a Cannon camera (Hanafy, unpublished). 
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Statistics 
Continuous variables were assessed for normality with skewness and kurtosis. All 
variables measured in this study were normally distributed and groups were compared 
with the Student’s t-test or ANOVA. If comparisons were made among groups analyzed 
by ANOVA, the Bonferroni correction was used. All statistical analyses were performed 
using Prism Software for Mac.  P <0.05 was considered statistically significant (Hanafy, 
2013). 
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RESULTS 
The first experiment conducted looked to see which immune system cells were 
most abundant in vivo through a six-day course of SAH pathology.  To do this, a FACS 
analysis was completed on three different WT SAH mice, each perfused at a different 
time point after surgery.  A SHAM model was used as a control, where normal saline 
(NS) was injected into the mouse instead of donor blood (Figure 2).  WT SAH mouse one 
was over-anesthetized at post-operative day (POD) 1, WT SAH mouse two at POD3, and 
WT SAH mouse three at POD6.  The FACS analysis was run using eight different 
antibodies, each specific for different immune cell biomarkers (Figure 2). Since only one 
mouse was used per time point, significance could not be drawn, and results were based 
on relevance and approaching significance. 
 
	  
Figure 2- FACS of WT SHAM mice, and WT SAH mice showing percentage of immune cells 
present at POD1, POD3, and POD6. The biomarkers are as follows: Cd11b: microglia, CD45.2: 
leukocyte common antigen, Gr1: granulocyte receptor 1-antigen, NK: natural killer cells, IAb: 
histocompatibility 2 (mainly dendritic cells), CD19: B-lymphocyte antigen, CD3: T-cell receptor 
antigen, CD8: T-cell receptor.  The percentage of immune cells at each time point is shown.  
Microglia and natural killer cells are shown to be major cells throughout the SAH time-course.   
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On PODs 1 and 3, microglia and natural killer cells are more abundant as 
compared to other cells sorted, with natural killer cell percentage slightly higher than 
microglia cell percentage on POD1 (2.5% difference), and the opposite trend seen on 
POD3 (4% difference).  On POD6, microglia cells are most abundant and show 8.5% 
more positive cells than the second most abundant cells, which are the natural killer cells.   
Before moving into the main hypothesis, a few experiments were completed to 
see if an in vivo model of microglia action could be replicated in vitro; that is to see if 
microglia treated with blood would phagocytose RBCs.  After treating BV2 microglia 
cells with RBCs for 3 hours, phagocytosis was seen using light microscopy imaging 
(Figure 3).  An RBC was counted as phagocytosed if the RBC was clearly visible inside 
the microglia cell and if the RBC had changed color from blue to yellow. 
 
	  
Figure 3 – Light Microscopy of BV2 cells after 3-hour RBC treatment.  The left picture is an 
untreated control.  In this picture, no phagocytosis can be seen.  The right picture is a BV2 well 
treated with RBCs.  The BV2 cells engulf the RBCs, as they do in vivo. 
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Figure 4 – Light Microscopy hour time course of PMGs phagocytosing RBCs. A: Picture 
taken at “time zero,” seconds after adding RBCs.  As seen here, phagocytosis occurs 
immediately after adding RBCs to the PMGs. B: Picture taken at 20-minute incubation time point. 
C: Picture taken at 40-minute incubation time point. D: Picture taken at 1-hour incubation time 
point.   WT PMG cells phagocytose RBCs in our in vitro model, mirroring known cell phagocytosis 
cell activity in vivo. 
 
 
To make sure that the same in vitro results were acquired with PMGs, a time 
course was conducted where PMG cells were viewed with light microscopy every 20 
minutes, ending at an hour time point (Figure 4).  As with the BV2s, the PMGs 
phagocytosed RBCs, and cellular morphology changes could be seen when the microglia 
interacted with the RBCs  
With the in vitro microglia shown to act similarly to in vivo microglia, the next set 
of experiments conducted looked to provide an SAH in vitro model to see how microglia 
clearance of RBC components, affected neuronal death.  To do this, PMGs or microglial 
BV2 cells were placed into transwells.  These cell culture inserts were then placed into 6-
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wells containing neuronal HT22 cells.  Transwells were used to avoid confounding 
factors such as microglial phagocytosis of neuronal cells.  Microglia have been shown to 
phagocytose and kill neurons when there is both direct contact between the two cells and 
microglia soluble mediators that induce neurons to express eat-me signals present (Neher 
et al., 2011).  Any pre-treatments were done before transwells with microglia were placed 
into HT22 filled wells.  RBCs and RBC components were added after microglia-filled 
transwells were placed in HT22 wells  
First, a time course of an SAH in vitro model was conducted.  BV2 cells were 
exposed to RBCs for different durations of time (1 hour, 3 hours, 12 hours, and 24 hours), 
and HT22 cell death was measured using TUNEL (Figure 5).  The longer the BV2 cells 
were exposed to RBCs, the more HT22 cell death was seen.  At each time point, the 
HT22 cell death was relatively greater in association with RBC treated BV2 cells as 
compared to untreated BV2 controls. 	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Figure 5 – IHC HT22 TUNEL assay time-course for BV2 Transwell experiment.  A time 
course for the BV2 transwell experiment is shown at 1-hour, 3-hour, 12-hour, and 24-hour time 
points.  As can be seen, more death occurs in the BV2 + RBC 12-hour and 24-hour incubation 
time points. 
 
 
To see if the same general trend held true with PMGs, WT PMGs were exposed to 
RBCs for 1 hour, 3 hour, and 12 hours (Figure 6).  The longer the WT PMGs were 
exposed to RBCs, the more HT22 cell death occurred.  For each time-point, there was 
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more HT22 cell death for the RBC exposed PMGs as compared to the unexposed 
samples.  	  
	  
Figure 6 – IHC HT22 FJC assay time-course for PMG Transwell experiment. A time course 
for the WT transwell experiment is shown at 1-hour, 3-hour and 12-hour.  HT22 apoptosis 
increases in the WT + RBC groups as the incubation time points increase. 	  	  	  
With the knowledge that more RBC exposure to either BV2 or WT PMGs causes 
more associated HT22 cell death, the next in vitro SAH experiments looked to see if the 
TLR4 pathway had a major role. Since 24 hour exposure showed the most HT22 cell 
death in association with BV2 cell cultures, it was chosen for the next SAH in vitro 
experiment (Figure 7).  To see if microgial BV2 TLR4 activation caused HT22 neuronal 
death, the next experiment included BV2 cells treated with both LPS and RBCs, and 
BV2s treated with RBCs only.  Similar HT22 cell death was present as measured by 
FloroJade C (FJC) staining in HT22s associated with the LPS and RBC treated BV2s and 
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BV2 cells treated with RBCs only.  Both treated groups showed more HT22 neuronal cell 
death than the untreated control. 
	  
	  
Figure 7 – IHC HT22 FloroJade staining at 24-hour time point. The top left IHC picture is an 
untreated BV2 control.  The top right IHC picture is an RBC treated BV2 well.  The bottom left 
IHC picture is an RBC treated BV2 well which was pre-treated with LPS.  	  	  
 
With microglial TLR4 activation shown to cause more HT22 cell death after a 24-
hour treatment as compared to an untreated control, the next experiment looked to see if 
TLR4, MyD88, and TRIF played a major role in neuronal apoptosis after only an hour of 
treatment.  To investigate this, PMGs harvested from transgenic knockout mice including 
TLR4-/-, MyD88-/-, and TRIF-/- were used in transwell experiments.  All sample wells 
were treated with RBCs except control wells, which were left untreated (Figures 8a & 
8b).  Interestingly, the WT PMG + RBC and MyD88-/- + RBC had similar HT22 
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apoptosis, but both groups had significantly more cell death than the WT control, TLR4  -
/- + RBC, and TRIF-/- + RBC HT22 cells (p<0.05). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Figure 8a - IHC Florojade HT22 staining at 1-hour time point for different genotypes.  Top 
left: Untreated WT PMG control.  Top right: WT PMG treated with RBCs.  Bottom left: TLR4-/- 
treated with RBCs.  Bottom middle: MyD88-/- treated with RBCs.  Bottom right: TRIF-/- treated 
with RBCs. 
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Figure 8b – HT22 Apoptosis Assay with FJC at 1-hour time point for different genotypes.  
The WT PMG and MyD88-/- RBC treated PMGs showed significant death compared to a WT 
untreated control (p<0.05).  Other genotype death was not significant. 
	  
Figure 9 - HT22 Apoptosis Assay with TUNEL at 1-hour time point for WT and MyD88-/- 
PMGs.  HT22 apoptosis was similar for the WT and MyD88-/- RBC treated PMGs.  Both WT and 
MyD88-/- showed more apoptosis relative to the WT untreated control. 
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To confirm the results from the FJC assay, the experiment was repeated for the 
WT control, WT + RBC, and MyD88-/- groups using TUNEL staining, which marks 
fragmented nuclei or cells that are apoptotic (Figure 9).  Again, the WT PMG + RBC and 
MyD88-/- showed similar HT22 apoptosis counts, but both grouped showed significantly 
higher HT22 cell death than the WT control. 
 
	  
Figure 10 - HT22 in vivo Apoptosis Assay with TUNEL at 1-hour time point for WT mice 
treated with RBC components.  WT mice treated with whole blood and hemoglobin had 
significant apoptosis as compared with a NS-treated control mouse (p<0.05). 
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As mentioned, research has shown that hemoglobin and heme are potential 
activators of the TLR4 pathway, which could thus lead to cell apoptosis (Lin et al., 2012; 
Wang et al., 2014).  These propositions were tested in an SAH in vivo model.  First, a 
TUNEL assay was conducted on WT mice induced with SAH using different blood 
components (Figure 10).  One group WT SAH mice were treated with whole blood, a 
second group of WT SAH mice were treated with hemoglobin, and a third group of WT 
mice were treated with hemin.  Hemin is an iron-containing metalloporphyrin with a 
chloride attached to the center iron and is chemically similar to heme; it was used for 
experiments in place of heme (RxList, 2014).   A fourth group of WT SHAM mice were 
treated with NS for comparison. The number of apoptotic neuronal cells was significantly 
higher in the cerebral sections of WT mice treated with whole blood and hemoglobin as 
compared to SHAM control mice (p<0.05).  To see if this held true in an in vitro model, 
the same experiment was repeated in WT PMG cell cultures using transwells, except the 
control was left untreated and HT22 cells were tested (Figure 11).  Similar results were 
found in vitro using a FJC assay.  Significance could not be obtained for this in vitro 
experiment due to small sample size. 
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Figure 11 - HT22 In vitro Apoptosis Assay with FJC at 1-hour time point for WT PMGs 
treated with RBC components.  WT PMG treated with whole blood and hemoglobin had more 
apoptosis as compared with an untreated control WT PMG. 	  	  	  
The final in vitro experiment looked back at the genotypes of interest to see if a 
difference in HT22 apoptosis was seen when treating each genotype knockout with 
different RBC components (Figure 12).  WT, TLR4-/-, MyD88-/-, and TRIF-/- PMGs 
were treated with blood and RBC components (RBCs, hemoglobin, or hemin), and each 
genotype had its own untreated control.  The blood component treated PMGs had higher 
HT22 cell apoptosis counts for each genotype when compared to each genotype’s 
untreated control.  MyD88-/- treated with RBCs, hemoglobin, or hemin showed the most 
HT22 apoptosis when compared with the other genotypes treated with the same blood 
component.  Hemoglobin treated cells showed the most apoptosis when comparing cell 
death for different blood components within each genotype. 
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Figure 12 - HT22 In vitro Apoptosis Assay with FJC at 1-hour time point for genotypes 
treated with RBC components.	  	  MyD88-­‐/-­‐	  treated	  with	  RBC,	  hemoglobin,	  and	  hemin	  had	  more	  HT22	  cell	  death	  compared	  with	  other	  genotypes	  treated	  with	  the	  same	  component.	  
	  
	  
	  
	  
Figure 13 – WT and TLR4-/- total errors performed during Barnes Maze.  TLR4-/- mice 
performed significantly less total errors than WT mice on POD5 and 6 (p<0.01).  SR: Spatial 
Reversal. 	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The last in vivo experiments conducted were to test how TLR4 expression 
affected cognitive outcome and behavioral performance in an SAH model.  To do this, 
Barnes Maze performance between three WT mice and three TLR4-/- mice were 
compared (Figures 13 & 14).  Interestingly, no significant differences were seen between 
the mice groups between SAH POD1-3 for both total errors and total latency.  
Differences were seen only after the spatial reversal was completed.  On POD5 and 6, the 
TLR4-/- performed less total errors as compared to WT mice and this was very 
significant (p<0.01).  On POD4 and 5, the TLR4-/- had a significantly shorter total 
latency time than the WT mice (p<0.05).  On POD6, the TLR4-/- total latency time was 
also shorter and this was very significant (p<0.01).   
	  
Figure 14 – WT and TLR4-/- total latency performed during Barnes Maze.  TLR4-/- mice took 
significantly less time to reach the goal chamber on POD4, POD5 (p<0.05), and POD6 (p<0.01).  
SR: Spatial Reversal. 
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Our experimental results suggest that a microglial TLR4-dependent, MyD88-
independent pathway is involved in neuronal apoptosis within the first hour of SAH via 
RBC and hemoglobin activation, and this mechanism may be microglial TRIF-dependent.   
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DISCUSSION 
The results presented give insight into the role of the TLR4 pathway in neuronal 
apoptosis as a result of SAH neuroinflammation. Our experimental results suggest that a 
microglial TLR4-dependent, MyD88-independent pathway is involved in neuronal 
apoptosis within the first hour of SAH via RBC and hemoglobin activation, and this 
mechanism may be microglial TRIF-dependent.   
The current hypothesis is that neuronal cell death is mediated via the innate 
immune system, specifically via a TLR4-dependent pathway.  Since TLR4 is expressed 
in a majority of cells, it was vital to conduct a FACS of in vivo tissues to see which 
immune cells are relatively most abundant during the first six days of SAH.  Figure 2 
shows that from POD1-6, the percentage of CD11b cells or microglia increases.  This 
suggests that microglia play an increasing role in the early phases of SAH. The 
abundance of natural killer cells in PODs 1, 3, and 6, as compared to other non-microglial 
immune cells, further shows that the innate immune system plays an important role in the 
early insult phase.   
On PODs 1 and 3, CD8 or T lymphocytes show a slight increase as compared to 
all other cells besides microglia and natural killer cells (2.5% difference). This suggests 
that the adaptive immune system may be involved in SAH pathology, although its role in 
early SAH is most likely limited.  By POD6, IAb cells or histocompatibility 2 positive 
cells are the third most abundant cells behind microglia and natural killer cells.  
Histocompatibility 2 positive cells are of the antigen-presenting type and are mainly 
represented by dendritic cells.  Dendritic cells have been previously shown to increase in 
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an alternate hemorrhage model (Hammond et al., 2012), although their exact role in SAH 
pathology remains unclear. 
In vivo, microglia are phagocytic cells that engulf material in the extracellular 
environment (Kumar, 2013) as is shown in the presented BV2 and PMG model (Figures 
3 & 4).  The phagocytosis of blood components including RBCs, hemoglobin, and hemin 
early in SAH pathology is most likely beneficial because a decrease in the total blood 
burden in the brain, would lead to a decrease in pressure.  The complete role of 
phagoytosis in relation to neuroinflammation in SAH remains unknown. 
It has been shown in previous research that RBC components can act as activators 
of TLR4 and thus microglia (Lin et al., 2012; Wang et al., 2014).  As was seen, the more 
time RBCs have to activate microglia, the more apoptosis is seen in the associated HT22 
cells (Figure 5).  When BV2s are treated with a well known, strong TLR4 activator (LPS) 
and RBCs at 24-hours, the same HT22 cell death occurs as with the samples treated with 
RBCs only (Figure 7).  These results suggest that blood interaction with microglia causes 
maximum TLR4 activation.  In theory, if RBCs were not maximally activating microglial 
TLR4 receptors, then more death should have been seen when LPS was also added to the 
sample, and this was not the case.  Therefore, the it is most likely that the RBCs or its 
components activated microglial TLR4 maximally at the 24-hour time point, and this lead 
to more HT22 death. 
To further investigate the RBC TLR4 activation of microglia, in vitro and in vivo, 
experiments on genotype knockout mice for TLR4, MyD88, and TRIF were run.  For the 
in vitro experiments, 1-hour incubations were set as the primary time point.  As expected, 
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the results showed that more HT22 cell apoptosis using FJC was seen in WT PMG + 
RBCs as compared to an untreated WT control (Figures 8a & 8b). What was newly 
discovered was that when MyD88-/- PMGs were exposed to RBCs, significant HT22 
apoptosis was also seen as compared to the control.  Importantly, the TLR4-/- and TRIF-
/- PMGs exposed to RBCs showed about as much HT22 apoptosis as the control.  This 
was the first indication that the MyD88 adaptor was not involved in HT22 apoptosis in 
the first hour of our model.  To further investigate that MyD88 was not involved in one-
hour HT22 cell apoptosis, another experiment was ran using TUNEL staining (Figure 
10).  Again, the death in WT + RBC and MyD88-/- + RBC was similar, and both showed 
more cell apoptosis than the control. 
When different RBC components in our SAH model were tested, whole blood 
(mainly RBCs) and hemoglobin showed significantly more HT22 apoptosis both in vivo 
(WT mice) and in vitro (WT PMGs), than hemin or controls (Figures 11 & 12).  When 
this experiment was repeated in genotype knockout PMGs, the HT22 cell apoptosis 
associated with MyD88-/- PMGs remained higher than the other genotypes (TLR4-/- and 
TRIF-/-) (Figure 14).  This gave further evidence that HT22 cell death in the first hour of 
blood exposure was MyD88 independent.  These results not only suggested that TLR4 
and TRIF are important in resulting HT22 cell apoptosis, but that hemoglobin may be the 
key RBC component that activates the pathway. 
  SAH is known to have adverse cognitive outcome in patients (Brainin & Heiss, 
2010).  Often, SAH patients have neuronal cell death in the hippocampus region that 
leads to memory loss.  To see if the presented TLR4 model had relevance to cognition 
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and behavioral deficits, TLR4-/- and WT mice performance on the Barnes Maze were 
compared.  As stated in the results, the TLR4-/- performed significantly better on most 
SAH POD days after the spatial reversal, except POD7  (Figures 13 & 14).  This 
indicates that overall, TLR4 activation after SAH is involved in working memory and 
spatial learning disruption, as well as behavioral function deficits. 
The presented experimental results suggest that a microglial TLR4-dependent, 
MyD88-independent pathway is involved in neuronal apoptosis very early in an SAH 
model (first hour of ictal event) via whole RBC and hemoglobin activation, and that 
neuronal cell apoptosis due to TLR4 expression may be related to SAH-related cognitive 
and behavioral deficits.  The results suggest that TRIF may be the intracellular adaptor 
that is involved in this mechanism, but further experiments are needed to confirm this.  
Currently, the Hanafy lab looking to complete another TUNEL assay on HT22s after 
exposing the associated TRIF PMGs to RBCs for an hour.  Many different pro-
inflammatory mediators such as cytokines are released by microglia after TLR4 
activation, which can cause neuronal apoptosis.  The Hanafy lab is currently running 
assays on TNF-a and other cytokines to see if these factors are involved in the cell death 
seen in the early SAH model.  The Hanafy lab is also completing additional experiments 
to see if other biomarkers may be involved in this mechanism after TLR4 activation.  The 
Barnes Maze experiment with SAH TLR4-/- mice shows that the TLR4 pathway may be 
involved in the neuronal death seen in SAH patients, which leads to cognitive and 
behavioral deficits.  The next experiment will be to test SAH MyD88-/- and SAH TRIF-/- 
mice performance using the Barnes Maze.  In conclusion, the presented results suggest 
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that a TLR4 dependent, MyD88-indepdent pathway may be a potential therapeutic target 
early in SAH pathology, and may help to reduce microglial TLR4-mediated neuronal 
apoptosis and related cognitive and behavioral deficits. 
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